T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms

Molecular Therapy

Volumn 18, Issue 11, 2010, Pages 2006-2017

  Sun, Jiali ^a,b   Dotti, Gianpietro ^a,b   Huye, Leslie E ^a   Foster, Aaron E ^a   Savoldo, Barbara ^a,b   Gramatges, Maria M ^b   Spencer, David M ^a,b   Rooney, Cliona M ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIBODY; CD3 ANTIBODY; CHIMERIC PROTEIN; CYTOKINE; DISIALOGANGLIOSIDE; GANGLIOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN ANTIBODY; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN; CELL STRAIN LAN 1; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 78049468066     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.185     Document Type: Article

References (47)

1. Rooney, CM, Smith, CA, Ng, CY, Loftin, S, Li, C, Krance, RA et al. (1995). Use of gene-modifed virus-specifc T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13.
2. Riddell, SR, Walter, BA, Gilbert, MJ and Greenberg, PD (1994). Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodefcient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 14 Suppl 4: S78-S84.
3. Rooney, CM, Smith, CA, Ng, CY, Loftin, SK, Sixbey, JW, Gan, Y et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
4. Straathof, KC, Bollard, CM, Popat, U, Huls, MH, Lopez, T, Morriss, MC et al. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specifc T lymphocytes. Blood 105: 1898-1904.
5. Dudley, ME, Wunderlich, JR, Yang, JC, Sherry, RM, Topalian, SL, Restifo, NP et al. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
6. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
7. Yee, C, Thompson, JA, Byrd, D, Riddell, SR, Roche, P, Celis, E et al. (2002). Adoptive T cell therapy using antigen-specifc CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173.
8. Hahne, M, Rimoldi, D, Schröter, M, Romero, P, Schreier, M, French, LE et al. (1996). Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366.
9. Thomas, DA and Massagué, J (2005). TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380.
10. Gorelik, L and Flavell, RA (2001). Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7: 1118-1122.
11. Dong, H, Strome, SE, Salomao, DR, Tamura, H, Hirano, F, Flies, DB et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
12. Iwai, Y, Ishida, M, Tanaka, Y, Okazaki, T, Honjo, T and Minato, N (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293-12297.
13. Curiel, TJ, Coukos, G, Zou, L, Alvarez, X, Cheng, P, Mottram, P et al. (2004). Specifc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
14. Yu, P, Lee, Y, Liu, W, Krausz, T, Chong, A, Schreiber, H et al. (2005). Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201: 779-791.
15. Dotti, G, Savoldo, B, Pule, M, Straathof, KC, Biagi, E, Yvon, E et al. (2005). Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105: 4677-4684.
16. Bollard, CM, Rössig, C, Calonge, MJ, Huls, MH, Wagner, HJ, Massague, J et al. (2002). Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99: 3179-3187.
17. Vera, JF, Hoyos, V, Savoldo, B, Quintarelli, C, Giordano Attianese, GM, Leen, AM et al. (2009). Genetic manipulation of tumor-specifc cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 17: 880-888.
18. Mehrotra, PT, Grant, AJ and Siegel, JP (1995). Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol 154: 5093-5102.
19. Foster, AE, Leen, AM, Lee, T, Okamura, T, Lu, A, Vera, J et al. (2007). Autologous designer antigen-presenting cells by gene modifcation of T lymphocyte blasts with IL-7 and IL-12. J Immunother 30: 506-516.
20. Manning, BD and Cantley, LC (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
21. Song, J, Lei, F T, Xiong, X and Haque, R (2008). Intracellular signals of T cell costimulation. Cell Mol Immunol 5: 239-247.
22. Wu, LX, La Rose, J, Chen, L, Neale, C, Mak, T, Okkenhaug, K et al. (2005). CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway. J Immunol 174: 180-194.
23. Schneider, H, Prasad, KV, Shoelson, SE and Rudd, CE (1995). CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med 181: 351-355.
24. Su, CC, Lin, YP, Cheng, YJ, Huang, JY, Chuang, WJ, Shan, YS et al. (2007). Phosphatidylinositol 3-kinase/Akt activation by integrin-tumor matrix interaction suppresses Fas-mediated apoptosis in T cells. J Immunol 179: 4589-4597.
25. Hähnel, PS, Thaler, S, Antunes, E, Huber, C, Theobald, M and Schuler, M (2008). Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res 68: 3899-3906.
26. Wohlfert, EA and Clark, RB (2007). 'Vive la Résistance!'-the PI3K-Akt pathway can determine target sensitivity to regulatory T cell suppression. Trends Immunol 28: 154-160.
27. Park, D, Lapteva, N, Seethammagari, M, Slawin, KM and Spencer, DM (2006). An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol 24: 1581-1590.
28. Kojima, H, Kanno, Y, Hase, H and Kobata, T (2005). CD4+CD25+ regulatory T cells attenuate the phosphatidylinositol 3-kinase/Akt pathway in antigen-primed immature CD8+ CTLs during functional maturation. J Immunol 174: 5959-5967.
29. Liu, VC, Wong, LY, Jang, T, Shah, AH, Park, I, Yang, X et al. (2007). Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178: 2883-2892.
30. Sauer, S, Bruno, L, Hertweck, A, Finlay, D, Leleu, M, Spivakov, M et al. (2008). T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 105: 7797-7802.
31. Haxhinasto, S, Mathis, D and Benoist, C (2008). The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 205: 565-574.
32. Rossig, C, Bollard, CM, Nuchtern, JG, Merchant, DA and Brenner, MK (2001). Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 94: 228-236.
33. Pulè, MA, Straathof, KC, Dotti, G, Heslop, HE, Rooney, CM and Brenner, MK (2005). A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12: 933-941.
34. Straathof, KC, Spencer, DM, Sutton, RE and Rooney, CM (2003). Suicide genes as safety switches in T lymphocytes. Cytotherapy 5: 227-230.
35. Ramos, CA, Asgari, Z, Liu, E, Yvon, E, Heslop, HE, Rooney, CM et al. (2010). An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 28: 1107-1115.
36. Strand, S, Hofmann, WJ, Hug, H, Müller, M, Otto, G, Strand, D et al. (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 2: 1361-1366.
37. Poppema, S, Potters, M, Visser, L and van den Berg, AM (1998). Immune escape mechanisms in Hodgkin's disease. Ann Oncol 9 Suppl 5: S21-S24.
38. Rooney, CM, Bollard, C, Huls, MH, Gahn, B, Gottschalk, S, Wagner, HJ et al. (2002). Immunotherapy for Hodgkin's disease. Ann Hematol 81 Suppl 2: S39-S42.
39. Piccirillo, CA and Shevach, EM (2001). Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167: 1137-1140.
40. Plunkett, FJ, Franzese, O, Finney, HM, Fletcher, JM, Belaramani, LL, Salmon, M et al. (2007). The loss of telomerase activity in highly differentiated CD8+CD28-CD27-T cells is associated with decreased Akt (Ser473) phosphorylation. J Immunol 178: 7710-7719.
41. Remy, I, Montmarquette, A and Michnick, SW (2004). PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 6: 358-365.
42. Lin, SJ, Chang, C, Ng, AK, Wang, SH, Li, JJ and Hu, CP (2007). Prevention of TGF-beta-induced apoptosis by interlukin-4 through Akt activation and p70S6K survival signaling pathways. Apoptosis 12: 1659-1670.
43. Battaglia, M, Stabilini, A and Roncarolo, MG (2005). Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105: 4743-4748.
44. Crellin, NK, Garcia, RV and Levings, MK (2007). Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 109: 2014-2022.
45. Pierau, M, Engelmann, S, Reinhold, D, Lapp, T, Schraven, B and Bommhardt, UH (2009). Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation. J Immunol 183: 6124-6134.
46. Greenberg, PD (1991). Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49: 281-355.
47. Fujio, Y and Walsh, K (1999). Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274: 16349-16354.